Several interesting combinations of therapies with Calquence for patients with CLL
Calquence, acalabrutinib, is a specific inhibitor of Bruton tyrosine kinase and a very effective and well-tolerated drug in treating CLL. At this year’s ASH Congress, several studies of combination therapies were presented, showing, according to Matthew Davids, that acalabrutinib will be a part of the combinations in the future. In this MEDtalk, Matthew Davids from the Dana Faber Cancer Institute in Boston, USA, gives his perspective on the combinations with acalabrutinib.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in